Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) on January 12 and set a price target of ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...

Trivariate Research has published a list of companies it said are candidates to announce another accelerated share repurchase ...

In the past 30 days, estimates for Halozyme Therapeutics’ 2024 earnings per share have Improved from $4.11 to $4.13.

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...

Sygnum Crypto Bank Raises $58M, Achieves Unicorn Status with $1B Valuation ...